The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F.
Sartori G, et al. Among authors: licenziato l.
Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27.
Br J Haematol. 2024.
PMID: 38011941